Abdulaziz AlGhamdi

Curious radiation oncologist #radonc #pedsradonc #sarcoma @queensu @UFProtontherapy @KFSHRC

[SARO @SARO_KSA]

Happening today
Register now !!

[SARO @SARO_KSA]

🚨 Join us for SARO Rounds

“The BART Trial – Rationale, Key Findings, and Clinical Implications”

🎤 Speaker: Dr. Vedang Murthy
🗣 Moderator: Dr. Mohammed Rizwanullah
📅 15 July 2026
⏰ 5:30 PM (KSA)
‼️ Registration Required:

https://t.co/ZMFtGHWDJr

Don’t miss this insightful discussion on the latest evidence from the BART trial and its impact on clinical practice.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Ian Tannock’s advice to future oncologist. A must-listen. https://t.co/tCZIgnQiU5

[Abdulaziz AlGhamdi @AZphotons]

@jaydetsky That’s amazing! The oracle has answered. There’s no reason to resort to a morbid procedure when simple, precise radiation can suffice. That’s my conclusion.

[JCO Oncology Practice @JCOOP_ASCO]

Phase II Trials in Radiation Oncology: When Success Fails to Translate. Co-authored by @NiuSanford and @DavidSherMD.

Read the full article. https://t.co/FHKEWVMyxC

#radonc

[SARO @SARO_KSA]

🚨 Join us at the Special SARO Rounds

“Using Lung SBRT to Bridge the Gap: Access, Efficiency, and Equity in Radiation Oncology”

🎤 Speaker: Dr. @DrewMoghanaki
🗣 Moderator: Dr. @othmanmo
📅 6 May 2026
⏰ 7 PM
‼️Registration Required:
https://t.co/omi1bDlAuk
Don’t miss this insightful session!

[Abdulaziz AlGhamdi @AZphotons]

@GregoryPaulin @DrSpratticus @eldredevans Good old science!

[Jeff Yang MD FACS @ChiFuJeffYang]

.@alexandra_p_24, @LeciaSequist and I wrote a new editorial in JAMA (https://t.co/6pULCORCnC) responding to a powerful #lungcancer screening study by Bandi et al (https://t.co/nJwm2KEinm). In 2024, only 18.7% of adults eligible for #lungcancerscreening in the U.S. were screened.
That means most people who should have had an early, treatable cancer found in time… never got that chance.

Even with uptake this low, screening is estimated to save nearly 15,000 lives over 5 years—these are parents, siblings, neighbors, friends. People who are alive today because a simple CT scan found their cancer early.

If every person who qualified under today’s criteria were screened, we could save at least 62,000 lives over 5 years. And the study shows 30,000 more lives could be saved over 5 years among people with a smoking history who don’t even qualify under current USPSTF criteria.

This is an urgent call to action: we need thoughtful but accelerated expansion of lung cancer screening eligibility — and far stronger outreach, access, and policy support to ensure screening reaches everyone who needs it.

[Shankar Siva @_ShankarSiva]

@DrewMoghanaki shows us why more patients with early stage #lungcancer will have SABR over surgery -#SABR2025

[Jeff Ryckman @jryckman3]

Interesting slide! #SABR2025

[Jeff Ryckman @jryckman3]

I wonder, is there such a study for IR-based methods vs. SABR in the liver? 🤔

If not, might be a great one to emulate! Bet >56% of ppl who rec’d IR-based methods to the liver have no prior knowledge of SABR. #SABR2025

@nbn426 @NiuSanford @KrishanJethwa @lauren_henke @tedradonc

[Joshua D. Palmer, MD @joshuapalmermd]

@ASTRO_org @ESTRO_RT @freddyeescorcia @NeuroOnc @ASCO @SNM_MI @OSUCCC_James @OhioStateRadOnc @OhioStateMedOnc

[Joshua D. Palmer, MD @joshuapalmermd]

Today, we successfully completed C1D1 treatment of our first patient on the Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter (PRIMe-STAR).

The first patient in the world to receive this therapy for meningioma!

☢️ RYZ101 (225Ac-DOTATATE)

[Amir Safavi @safaviaa]

We have adopted 40 Gy ENI for HPV+ definitive and postop cases at Sunnybrook. At MSKCC, 30 Gy ENI used for HPV+ with chemo (Tsai 2022 JAMAOnc, Safavi 2025 IJROBP abstract) and 40 Gy ENI in HPVneg with chemo (Zakeri Head Neck 2025). Others using doses in this range as well (UPGRADE-RT, INFIELD, Deschuymer Radiother Oncol 2020). Review here summarizes data and considerations: https://t.co/8GTqyyTET1
Sequential planning needed to use these much lower doses.

need comprehensive staging and identification of seemingly borderline nodes to boost appropriately to 60-70 Gy. Recent JCOG trial did not require PET staging and most nodal failures were in existing “marginal” nodes per reports of the presentation; full manuscript needed and perhaps PET would have helped to better identify these nodes. UPGRADE-RT had thorough definitions for borderline nodes. On the other hand 50 Gy EQD2 likely not enough to treat such nodes either, so identification of subtle already involved nodes and ENI for microscopic disease may be parallel but ultimately separate issues.

[rob tibshirani @robtibshirani]

Please repost and forward this message on any platform as widely as possible so I can get some insurance relief. In my 20 years as a primary care doctor, insurance has corroded doctors' abilities to treat patients as human beings.

[rob tibshirani @robtibshirani]

is an FDA approved therapy for my specific cancer prescribed by one of the leading thoracic oncologists in the world!
5) If my appeal is denied, what is going to happen to me?

[rob tibshirani @robtibshirani]

and the CT scan showed spreading cancer in my chest. I urgently need new treatment as my symptoms have all worsened. 4) *AETNA* just denied "prior authorization" for potentially life-saving/life-prolonging treatment with Rybrevant (amivantamab - Johnson & Johnson).

[rob tibshirani @robtibshirani]

and other media outlets. At least I could turn my misfortune into a little bit of good.
3) Thanks to amazing advances in treatment with Tagrisso (osimertinib - AstraZeneca), I have survived progression free until a couple of weeks ago when my cough came back

[rob tibshirani @robtibshirani]

From Dr. Bryant Lin, Stanford
I'm living in insurance hell!!!
1) I am a Stage 4 Lung Cancer patient and advocate.
2) As a medical school Clinical Professor, I taught a class at Stanford anchored around my own case which was covered widely in the The New York Times, CBS Mornings,

[Abdulaziz AlGhamdi @AZphotons]

@5_utr I can’t believe this is considered an oncologic endpoint. We already know that durvalumab plus chemotherapy can shrink tumors from the KEYNOTE-816 trial. So what exactly is the purpose of this STUDY?